TY - JOUR
T1 - Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy
T2 - Ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association
AU - Uderzo, Cornelio
AU - Valsecchi, Maria Grazia
AU - Bacigalupo, Andrea
AU - Meloni, Giovanna
AU - Messina, Chiara
AU - Polchi, Paola
AU - Di Girolamo, Gabriele
AU - Dini, Giorgio
AU - Miniero, Roberto
AU - Locatelli, Franco
AU - Colella, Roberto
AU - Tamaro, Paolo
AU - Lo Curto, Margherita
AU - Di Tullio, Maria Teresa
AU - Masera, Giuseppe
PY - 1995/2
Y1 - 1995/2
N2 - Purpose: To compare the results of allogeneic bone marrow transplantation (AlloBMT) with those obtained with chemotherapy (CHEMO) in children with acute lymphoblastic leukemia (ALL) in second complete remission (CR) after a marrow relapse. The experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatrie Hematology Oncology Association is summarized. Patients and Methods: All children who had a relapse in the period 1980 to 1989 in 27 centers in Italy were eligible for the study. Of 287 eligible patients, 230 were treated with CHEMO, most of them (93%) according to a standard multiple-drug relapse protocol. The remaining 57 children underwent AlIoBMT. Preparative regimens included total-body irradiation and chemotherapy (n = 51) or chemotherapy alone (n = 6). Statistical analysis was performed with a Cox regression model adjusting for waiting time to transplant and prognostic factors. Results: In the whole series, minimum and median follow-up after second CR were 3 and 6.2 years, respectively; at 8 years from second CR, disease-free survival (DFS) was 20.0% (SE 2.5) and survival was 26.4% (SE 2.9). In the group of patients with an early first relapse, DFS was significantly longer after AIIoBMT than after CHEMO (relative risk [RR] = 0.45, P = .002). No significant advantage of AIIoBMT over CHEMO was found for patients with a late relapse (> 30 months since diagnosis). Duration of first CR significantly influenced prognosis in the CHEMO group (RR = 0.32, P = .0001 for patients with late first relapse versus patients with early first relapse). Conclusion: Results suggest an advantage in DFS of AIIoBMT over CHEMO in ALL patients who experienced an early first medullary relapse. Prospective trials are needed to address efficacy of AIIoBMT versus CHEMO in patients with late bone marrow relapse. J Clin Oncol 13:352-358.
AB - Purpose: To compare the results of allogeneic bone marrow transplantation (AlloBMT) with those obtained with chemotherapy (CHEMO) in children with acute lymphoblastic leukemia (ALL) in second complete remission (CR) after a marrow relapse. The experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatrie Hematology Oncology Association is summarized. Patients and Methods: All children who had a relapse in the period 1980 to 1989 in 27 centers in Italy were eligible for the study. Of 287 eligible patients, 230 were treated with CHEMO, most of them (93%) according to a standard multiple-drug relapse protocol. The remaining 57 children underwent AlIoBMT. Preparative regimens included total-body irradiation and chemotherapy (n = 51) or chemotherapy alone (n = 6). Statistical analysis was performed with a Cox regression model adjusting for waiting time to transplant and prognostic factors. Results: In the whole series, minimum and median follow-up after second CR were 3 and 6.2 years, respectively; at 8 years from second CR, disease-free survival (DFS) was 20.0% (SE 2.5) and survival was 26.4% (SE 2.9). In the group of patients with an early first relapse, DFS was significantly longer after AIIoBMT than after CHEMO (relative risk [RR] = 0.45, P = .002). No significant advantage of AIIoBMT over CHEMO was found for patients with a late relapse (> 30 months since diagnosis). Duration of first CR significantly influenced prognosis in the CHEMO group (RR = 0.32, P = .0001 for patients with late first relapse versus patients with early first relapse). Conclusion: Results suggest an advantage in DFS of AIIoBMT over CHEMO in ALL patients who experienced an early first medullary relapse. Prospective trials are needed to address efficacy of AIIoBMT versus CHEMO in patients with late bone marrow relapse. J Clin Oncol 13:352-358.
UR - http://www.scopus.com/inward/record.url?scp=0028888924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028888924&partnerID=8YFLogxK
M3 - Article
C2 - 7844596
AN - SCOPUS:0028888924
SN - 0732-183X
VL - 13
SP - 352
EP - 358
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 2
ER -